52407-92-8 Usage
Uses
Used in Pharmaceutical Industry:
3-METHYL-3,8-DIAZA-BICYCLO[3.2.1]OCTANE DIHYDROCHLORIDE is used as a therapeutic agent for the treatment of obesity due to its ability to reduce food intake and body weight in animal models. Its action as a neuropeptide Y2 receptor antagonist suggests that it could help regulate appetite and energy balance, offering a potential solution for weight management.
Used in Metabolic Disorders Treatment:
In the field of metabolic disorders, 3-METHYL-3,8-DIAZA-BICYCLO[3.2.1]OCTANE DIHYDROCHLORIDE is used as a potential treatment for conditions such as type 2 diabetes and cardiovascular diseases. Its influence on energy balance and food intake regulation may contribute to the management of these disorders, although further research is required to confirm its efficacy and safety in human applications.
Used in Preclinical Research:
3-METHYL-3,8-DIAZA-BICYCLO[3.2.1]OCTANE DIHYDROCHLORIDE is utilized in preclinical studies as a research tool to investigate the role of the neuropeptide Y2 receptor in appetite regulation and energy homeostasis. These studies are crucial for understanding the mechanisms underlying obesity and related metabolic disorders, and for evaluating the compound's potential as a therapeutic agent.
Further research and clinical trials are necessary to fully assess the safety and efficacy of 3-METHYL-3,8-DIAZA-BICYCLO[3.2.1]OCTANE DIHYDROCHLORIDE for human use in the treatment of obesity and other related conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 52407-92-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,4,0 and 7 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 52407-92:
(7*5)+(6*2)+(5*4)+(4*0)+(3*7)+(2*9)+(1*2)=108
108 % 10 = 8
So 52407-92-8 is a valid CAS Registry Number.
InChI:InChI=1/C7H14N2.2ClH/c1-9-4-6-2-3-7(5-9)8-6;;/h6-8H,2-5H2,1H3;2*1H
52407-92-8Relevant academic research and scientific papers
CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS
-
Page/Page column 68, (2009/06/27)
The invention encompasses compounds of formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV
Compounds for the Treatment of Hepatitis C
-
, (2008/12/07)
The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
Compounds for the Treatment of Hepatitis C
-
, (2008/12/06)
The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
-
Page/Page column 50, (2008/06/13)
The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
